Real-world Insights & Economic Considerations in Type 2 Diabetes

Large claims databases offer a unique opportunity to examine year-to-year trends in diabetes population management. Intarcia Therapeutics, Inc., sponsored a study conducted by Milliman, a well-known source of actuarial expertise to the healthcare industry, to develop this whitepaper, which highlights the relationship between glycemic control and medication adherence.

Download the paper to discover:

• Trends in HbA1c and diabetes drug adherence
• Challenge of sustaining glycemic control and diabetes drug adherence over time
• Association between healthcare costs and HbA1c levels
• Correlation between glycemic control and medication adherence, including drug therapy characteristics